# OV01 Preference Label 1 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_297_Vasquell - Task 1, batch 20260615_082222).
Current status: DRAFT for read-and-own. No platform entry without Alexander's authorization for that exact step.

Studio-selected pair:
- Transcript A = 0.900, 15 steps, 11m 34s.
- Transcript B = 0.720, 15 steps, 5m 39s.
- Bundle IDs not shown in the pasted transcript; record from the download icons on submit.

Basis: both deliverable summaries read against `golden-OV01-v1.docx` and `grader-guidelines-OV01.txt`. This is a both-pass pair (A 0.90 sits just under the 0.93 catcher; B 0.72 is a low pass above the 0.40 and 0.50 enoxaparin floors), so it is a quality comparison, not a both-floor severity comparison. The golden discontinues the carried-forward inpatient enoxaparin at discharge.

KEY FINDING: A is better. Both are strong line-by-line reconciliations that get most of Section A right: both stop the carried-forward IV piperacillin-tazobactam and call for a deep-culture-directed, renally dosed step-down; both keep metformin, empagliflozin, and lisinopril held as explicit deferred restarts; both retain acetaminophen and avoid NSAIDs; both continue home insulin; and both catch the two home medications (ferrous sulfate and cholecalciferol) dropped from the order set. The decisive axis is the central designed item, the carried-forward inpatient enoxaparin. The golden discontinues it at discharge as inpatient-only prophylaxis that adds bleeding risk on aspirin and clopidogrel. Neither output cleanly discontinues it, so neither is a full catch, but A is materially closer: A flags that there is no atrial fibrillation or VTE indication, foregrounds the triple-antithrombotic bleeding risk, and asks whether it is still indicated at discharge with a defined stop criterion, while B accepts it as reasonable prophylaxis and only asks to bound the duration. A's disposition leans toward stopping; B's leans toward continuing. B's one edge is antibiotic restraint: it defers the exact agent to infectious disease per the golden, while A names specific agents.

VERDICT: A2 (A better). Button = A+ (one plus sign).

## Justification

Scale Selection: A+

Justification: Output A is preferred over Output B. The decisive axis is the central designed item, the carried-forward inpatient enoxaparin. The golden discontinues enoxaparin at discharge: it is inpatient-only VTE prophylaxis that the order set carried forward, it is not a home medication, and continuing it adds bleeding risk on aspirin and clopidogrel. Output A does not cleanly discontinue it, but it moves in the right direction: it flags that there is no atrial fibrillation or VTE indication, foregrounds the triple-antithrombotic bleeding risk that is the golden's stated reason to stop, and asks the physician to confirm whether it is still indicated at discharge with a defined stop criterion. Output B instead calls it reasonable prophylaxis for reduced mobility and asks only to tie it to a concrete endpoint, which accepts continuation rather than questioning it. On the item the task is built around, Output A is the less wrong of the two. The two are close on the rest of the list and both stop short of a clean discontinuation, so this is A+ (A avoids the error B makes on the central item) rather than A++ (A does not fully catch the trap) or plain A (the central-item difference is more than a narrow point).

Prompt adherence: Both deliver the requested sign, change, or stop verdict with a short why for every queued order, write plain-language patient instructions, and flag the items to confirm before signing. Both answer the full workflow. Tie.

Correctness: Both are correct on the non-central Section A items: stop the carried-forward IV piperacillin-tazobactam, hold metformin, empagliflozin, and lisinopril as explicit deferred restarts, retain acetaminophen with no NSAID, continue home insulin, and rank the deep-tissue culture above the superficial swab. Output A is more correct on the decisive item: it questions the enoxaparin indication and the triple-antithrombotic bleeding risk, which is the golden's basis for discontinuation. Output B accepts enoxaparin as reasonable prophylaxis, which is the wrong direction. Output B's one correctness edge is antibiotic restraint: it defers the exact agent to infectious disease, matching the golden, whereas Output A names specific agents (cephalexin, clindamycin, cefazolin) that the golden leaves to physician confirmation. That edge does not outweigh the central item.

Completeness: Both cover all fourteen queued orders, both add back the two omitted home medications (ferrous sulfate and cholecalciferol), and both produce patient instructions and a confirm-before-sign list. Neither omits required content. Both still describe the enoxaparin injection in the patient instructions rather than stopping it, so neither completes the central item, but Output A presents it as conditional with an explicit stop-criterion request while Output B presents it as a shot to continue with teaching. Slight edge A.

Methodology: Both read the full chart, reconcile the order set against the home list and the medication administration record, and correctly rank the deep-tissue culture above the superficial swab. The difference is the carried-forward enoxaparin: Output A treats the carried-forward order as something to re-derive and questions its home indication, while Output B treats it as an established prophylaxis to bound. Output A's method is closer to the re-derivation the task rewards.

Quality and clarity: Both are organized, signable reviews with clear tables and Spanish-ready patient instructions. The grader directs not to weight formatting, so this dimension is neutral.

Summary: Output A is preferred at A+ because it handles the central designed item more correctly. It questions whether the carried-forward inpatient enoxaparin is still indicated at discharge and foregrounds the triple-antithrombotic bleeding risk that the golden uses to discontinue it, while Output B accepts it as reasonable prophylaxis and only asks to bound the duration. Both are correct on the other Section A items and both stop short of a clean discontinuation, so the margin is A+ (A avoids B's acceptance of continuation), not A++ (A does not fully catch the trap). Output B's only edge, deferring the antibiotic agent to infectious disease, does not offset the central axis.

## Guardrails (must survive any edit)
1. Preferred output is A. Button = A+ (one plus sign).
2. The decider is the central designed item, the carried-forward inpatient enoxaparin. The golden discontinues it at discharge. A questions the indication and the triple-antithrombotic bleeding risk (closer to discontinue); B accepts it as reasonable prophylaxis and only bounds it. Do not recharacterize A as a clean catch; neither output discontinues it.
3. Margin is A+ (A2), not A++ (A3): A does not cleanly discontinue enoxaparin, so it is "A avoids B's error," not "A catches the trap B fails." Not plain A (A1) either, because the central-item difference is more than a narrow point and the grader gap is 0.18.
4. Both are correct on the other Section A items (stop pip-tazo, hold the three oral agents as explicit deferrals, no NSAID, continue insulin, deep-culture-directed renally dosed antibiotic, add back ferrous sulfate and cholecalciferol). Do not treat those as differentiators.
5. B's deferral of the exact antibiotic agent to infectious disease matches the golden and is a small point for B; A naming specific agents is a minor over-specification. This does not flip the preference.
6. PL 1 of 3 for OV01. Two more on different trajectory pairs remain.

## Submit mechanics
Select A+ (one plus sign), paste the justification from "Scale Selection: A+" through the Summary into Comments, submit the preference, confirm it appears in submission history, then run Preference Labels AutoQC. Do not submit until Alexander authorizes this exact step.
